EUVIMEDEUVIMED entdecken
Crossref

Optimizing Patient Selection for Bevacizumab Plus Irinotecan in Recurrent High Grade Glioma: Superiority of the Neutrophil-to-Lymphocyte Ratio Over Other Systemic Inflammation Indices

Sibel Oyucu Orhan, Bedrettin Orhan, Ulviyya Hasanzade, Seda Sali, Burcu Caner, Birol Ocak, Ahmet Bilgehan Şahin, Adem Deligönül, Erdem Çubukçu, Türkkan Evrensel

Eurasian Journal of Medical Investigation · 2026 · 37-45

DOI: 10.14744/ejmi.263037 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Eurasian Journal of Medical Investigation, 2026. Verfasst von Sibel Oyucu Orhan und 9 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Recurrent high-grade gliomas (rHGG) pose a significant challenge with poor prognosis. While bevacizumab plus irinotecan (BEV+IRI) is a frequent salvage regimen, clinical outcomes exhibit substantial inter-patient heterogeneity. Therefore, accessible prognostic biomarkers are needed to identify patients most likely to benefit.

Methods

This retrospective, single-center study enrolled adults with recurrent WHO grade 3–4 gliomas treated with BEV+IRI. Pre-treatment laboratory data were used to calculate Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lym-phocyte Ratio (PLR), Systemic Immune-Inflammation Index (SII), Pan-Immune-Inflammation Value (PIV), and hemoglobin, albumin, lymphocyte, platelet (HALP) scores. Optimal cut-offs were determined via receiver operating characteristics (ROC) analysis. Survival was analyzed using Kaplan-Meier and Cox regression models.

Results

In 43 patients, median overall survival (OS) was 9.6 months; median progression free survival (PFS) was 5.8 months. Patients with high pre-treatment NLR (≥6.74) had significantly shorter OS (4.4 vs. 11.4 months; p

Zitieren

APA

Orhan, S. O., Orhan, B., Hasanzade, U., Sali, S., Caner, B., Ocak, B., Şahin, A. B., Deligönül, A., Çubukçu, E., & Evrensel, T. (2026). Optimizing Patient Selection for Bevacizumab Plus Irinotecan in Recurrent High Grade Glioma: Superiority of the Neutrophil-to-Lymphocyte Ratio Over Other Systemic Inflammation Indices. Eurasian Journal of Medical Investigation, 37-45. https://doi.org/10.14744/ejmi.263037

Vancouver

Orhan SO, Orhan B, Hasanzade U, Sali S, Caner B, Ocak B, et al. Optimizing Patient Selection for Bevacizumab Plus Irinotecan in Recurrent High Grade Glioma: Superiority of the Neutrophil-to-Lymphocyte Ratio Over Other Systemic Inflammation Indices. Eurasian Journal of Medical Investigation. 2026:37-45. doi:10.14744/ejmi.263037

BibTeX
@article{Orhan2026,
  author = {Orhan, Sibel Oyucu and Orhan, Bedrettin and Hasanzade, Ulviyya and Sali, Seda and Caner, Burcu and Ocak, Birol and Şahin, Ahmet Bilgehan and Deligönül, Adem and Çubukçu, Erdem and Evrensel, Türkkan},
  title = {Optimizing Patient Selection for Bevacizumab Plus Irinotecan in Recurrent High Grade Glioma: Superiority of the Neutrophil-to-Lymphocyte Ratio Over Other Systemic Inflammation Indices},
  journal = {Eurasian Journal of Medical Investigation},
  year = {2026},
  pages = {37--45},
  doi = {10.14744/ejmi.263037}
}
Kostenlos starten →